•  
  •  
  •  
  •  

2023-12-11 02:15:18

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Tata Motors announces price increase of its commercial vehicles from January 2024
  • Shriram Properties extends relief to Chennai residents affected by Cyclone Michaung
  • Jaykay Enterprises Ltd executes MoU with Philips Machine Tools India Pvt Ltd
  • Viksit Bharat Sankalp Yatra camp organized by Indian Overseas Bank
  • CSC Academy and TeamLease Edtech's Digivarsity join hands with the Govt. of Jharkhand on a joint mission towards 'Making Jharkhand Employable'

Keywords Selected:  INE010B01027

Research

  • Quant Pick - Cadila Healthcare - ICICI Direct

Stock Report

  • Zydus receives Final Approval from the USFDA for Methylene Blue Injection
  • Sentynl Therapeutics Completes Asset Transfer of CUTX-101 from Cyprium Therapeutics
  • Zydus receives final approval from the USFDA for Ivabradine Tablets, 5 mg and 7.5 mg
  • Zydus and Guardant Health to jointly promote the Guardant360® portfolio of nextgeneration genomic tests for advanced solid cancers in India and Nepal
  • Zydus acquires UK based LiqMeds® Group
  • Zydus appoints Mr. Punit Patel as President and CEO to lead its business operations in North America
  • Zydus receives final approval from the USFDA for Sugammadex Injection, Single-Dose Vial
  • Zydus announces IND clearance of a novel Anti-PCSK9 candidate
  • Zydus receives final approval from the USFDA for Clindamycin Phosphate Gel USP, 1%
  • Zydus receives EIR for the formulation manufacturing facility at SEZ 2, Ahmedabad
  • Zydus receives final approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day
  • Zydus receives EIR for the injectables manufacturing facility at Zydus Biotech Park, Ahmedabad
  • Zydus receives final approval from the USFDA for Erythromycin Tablets USP, 250 mg and 500 mg
  • Zydus receives final approval from the USFDA for Isotretinoin Capsules USP, 10 mg, 20 mg 30 mg and 40 mg
  • Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders®
  • Zydus receives final approval from the USFDA for Zinc Sulfate Injection Pharmacy Bulk Package Vials
  • Zydus receives Final Approval from the USFDA for Indomethacin Suppository with Competitive Generic Therapy designation
  • Zydus receives final approval from the USFDA for Plerixafor Injection USP, 24 mg/1.2 mL (20 mg/mL), Single-Dose Vial
  • USFDA inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad concludes with nil observations
  • Zydus receives final approval from the USFDA for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg
  • Zydus receives EIR from the USFDA for its SEZ 1 manufacturing facility at Pharmez, Ahmedabad
  • Zydus receives tentative approval from the USFDA for Palbociclib Tablets, 75 mg, 100 mg, and 125 mg
  • Zydus receives final approval from the USFDA for Minocycline Hydrochloride Extended-Release Tablets USP, 55 mg, 65 mg, and 115 mg
  • USFDA inspection at Zydus' injectables manufacturing facility at Zydus Biotech Park, concludes with Nil observations

Latest Post

  • Tata Motors announces price increase of its commercial vehicles from January 2024
  • Shriram Properties extends relief to Chennai residents affected by Cyclone Michaung
  • Jaykay Enterprises Ltd executes MoU with Philips Machine Tools India Pvt Ltd
  • Viksit Bharat Sankalp Yatra camp organized by Indian Overseas Bank
  • CSC Academy and TeamLease Edtech's Digivarsity join hands with the Govt. of Jharkhand on a joint mission towards 'Making Jharkhand Employable'


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2022